Skip to main content

RNAi / siRNA Deal Benchmarks in Rare Disease

Median Upfront
$456M
Range: $223M - $688M
Total Deal Value
$2.5B
Range: $1.4B - $3.5B
Royalty Rate
8.2% - 16.4%
Tiered up to 20.4%
Dev Milestones
$441M
Range: $265M - $617M
Model Your Deal

Market Analysis

RNAi / siRNA therapies in rare disease have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 rnai / sirna asset in rare disease is $456M, with total deal values reaching $2.5B. Development milestones average $441M, while regulatory milestones contribute $501M.

The rare disease rnai / sirna landscape is characterized by limited competitive intensity per indication but growing platform competition. Gene therapies and oligonucleotide-based approaches are transforming treatment paradigms, with orphan designations enabling premium pricing and accelerated regulatory paths. The recommended deal structure allocates approximately 19% to upfront payments and 81% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for rnai / sirna rare disease deals range from 8.2% to 16.4% at the base tier, with tiered escalation reaching 12.2%-20.4% on blockbuster sales. Commercial milestones averaging $1.1B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a rnai / sirna rare disease licensing deal?
Based on our analysis, Phase 2 rnai / sirna licensing deals in rare disease average $456M in upfront payments, with a range of $223M to $688M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for rnai / sirna rare disease transactions?
The median total deal value for Phase 2 rnai / sirna assets in rare disease is $2.5B, ranging from $1.4B to $3.5B. This includes development milestones ($441M), regulatory milestones ($501M), and commercial milestones ($1.1B).
What royalty rates are standard for rnai / sirna deals in rare disease?
Base royalty rates for rnai / sirna rare disease transactions range from 8.2% to 16.4%, with tiered escalations reaching 12.2%-20.4% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in rnai / sirna rare disease deals?
RNAi / siRNA rare disease deals allocate approximately 81% of total deal value to milestones. Development milestones ($441M) make up the largest share, followed by commercial milestones ($1.1B) and regulatory milestones ($501M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Gene Therapy in Rare Disease

View

Small Molecule in Rare Disease

View

RNAi / siRNA in Oncology

View

RNAi / siRNA in Neurology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included